Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.57 +0.64 (+1.31%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock at a Reasonable Valuation ↗

July 16, 2025

NOVO-NORDISK (NYSE:NVO) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks in the pharmaceutical sector.

Via Chartmill

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗

July 16, 2025

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

Via Benzinga

Topics Government World Trade

10 Health Care Stocks Whale Activity In Today's Session ↗

July 15, 2025

Via Benzinga

3 Absurdly Cheap Growth Stocks to Load Up On Right Now ↗

July 15, 2025

Via The Motley Fool

Topics World Trade

How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes ↗

July 14, 2025

An update on Sana Biotechnology.

Via Benzinga

3 Dividend Growth Stocks to Buy and Hold ↗

July 12, 2025

Via The Motley Fool

Topics Intellectual Property

Magnificent 7 Crush EU Giants—Jamie Dimon Tells Europe: 'You're Losing' ↗

July 11, 2025

Jamie Dimon warns Europe is falling behind the U.S. economically. Market caps show an even wider gap as U.S. tech giants dominate.

Via Benzinga

3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly ↗

July 09, 2025

Via The Motley Fool

Zepbound Powers Eli Lilly's Upbeat Q2 Outlook ↗

July 09, 2025

BofA slightly raised Q2 estimates for Eli Lilly ahead of earnings as Zepbound sales improve; long-term forecasts for key drugs remain steady.

Via Benzinga

Dow Futures Edge Up As Trump Prepares More Tariff Letters: Freeport, UnitedHealth, Meta, Novo Nordisk, AstraZeneca Among Stocks In Focus ↗

July 09, 2025

While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%.

Via Stocktwits

Topics ETFs Government Stocks

Novo Nordisk Seeks Approval For Higher Wegovy Dose In Europe ↗

July 08, 2025

In addition to the submission to the EMA, Novo Nordisk aims to make the higher dose of Wegovy widely available throughout the European Union.

Via Stocktwits

Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval ↗

July 08, 2025

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Via Benzinga

WeightWatchers Sheds $1.15 Billion In Debt To Fuel Transformation ↗

July 08, 2025

WeightWatchers completes reorganization, adds new leadership and unveils a women's health initiative targeting menopause care.

Via Benzinga

2 S&P 500 Dividend Stocks That Could Climb 17% or More, According to Wall Street ↗

July 08, 2025

Via The Motley Fool

Topics Stocks

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround ↗

July 07, 2025

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.

Via Benzinga

Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits ↗

July 07, 2025

Hims & Hers faces stock pressure after Novo Nordisk ends Wegovy access, citing compounding violations and marketing concerns.

Via Benzinga

Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert ↗

July 07, 2025

Via Benzinga

Better Growth Buy: Eli Lilly vs. Viking Therapeutics ↗

July 07, 2025

Via The Motley Fool

2 Stocks to Buy on the Dip and Hold for 10 Years ↗

July 06, 2025

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 02, 2025

Via Benzinga

Is Hims & Hers Stock in Trouble? ↗

July 02, 2025

Via The Motley Fool

Topics Supply Chain

Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report ↗

July 01, 2025

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Via Benzinga

Amazon Wants More Power ↗

July 01, 2025

Amazon's latest data center will reportedly require the same amount of electricity as 1 million homes.

Via The Motley Fool

Topics Artificial Intelligence

Got $200? 2 Biotech Stocks to Buy and Hold Forever ↗

July 01, 2025

Via The Motley Fool

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗

June 30, 2025

The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.

Via Investor's Business Daily

Circle Internet, Hims & Hers Health And CoreWeave Are Among Top 10 Large Cap Losers Last Week (June 23-27): Are The Others In Your Portfolio? ↗

June 29, 2025

Last week's worst performers include CRCL, HIMS, VG, QXO, CRWV, DUOL, EQIX, EQNR, CF, and EC. Are they in your portfolio?

Via Benzinga

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

June 29, 2025

Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value

Via MarketBeat

Topics Artificial Intelligence Economy

Benzinga Bulls And Bears: Nvidia, Micron, HIMS — And Markets Soar On Mideast And Tariff Relief ↗

June 28, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs ↗

June 27, 2025

MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations.

Via Benzinga

Elon Musk Backs Satya Nadella's View That AI Must Produce 'Socially Useful' Results: 'The Real Question In The Next Five Years Is...' ↗

June 27, 2025

Tesla (NASDAQ: TSLA) CEO Elon Musk endorsed Microsoft (NASDAQ: MSFT) Satya Nadella's perspective on the practical impact of AI, emphasizing its benefits to sectors like healthcare, education, and...

Via Benzinga

Topics Artificial Intelligence

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today